Failed early
Temelimab: reduce relapses and new lesions in relapsing MS
relapsing MS · Antiviral / EBV-targeting
Controlled phase 2 trials were negative.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 270
Deciding trials (phase 2): 0 met, 1 did not.
Other linked trials: 0
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 2 · 2016 · Placebo-controlled · MSFT-NCT02782858
The primary endpoint was not met.
Read by software from the paper's abstract
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Failed early
Related hypotheses
- Antiviral / EBV-targeting: protect nerve tissue in relapsing MS
- Antiviral / EBV-targeting: repair myelin in relapsing MS
- Antiviral / EBV-targeting: reduce relapses and new lesions in relapsing MS
- Lactose, anhydrous: reduce relapses and new lesions in relapsing MS
- Raltegravir: reduce relapses and new lesions in relapsing MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error